These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 27324108)

  • 21. Olaparib for the treatment of breast cancer.
    Robert M; Frenel JS; Gourmelon C; Patsouris A; Augereau P; Campone M
    Expert Opin Investig Drugs; 2017 Jun; 26(6):751-759. PubMed ID: 28395540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
    Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
    Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The expression of APE1 in triple-negative breast cancer and its effect on drug sensitivity of olaparib.
    Chen T; Liu C; Lu H; Yin M; Shao C; Hu X; Wu J; Wang Y
    Tumour Biol; 2017 Oct; 39(10):1010428317713390. PubMed ID: 29064327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
    Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC
    Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer.
    Le D; Gelmon KA
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):833-839. PubMed ID: 30118334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Defective DNA repair mechanisms in prostate cancer: impact of olaparib.
    De Felice F; Tombolini V; Marampon F; Musella A; Marchetti C
    Drug Des Devel Ther; 2017; 11():547-552. PubMed ID: 28280302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies.
    Swaisland H; Plummer R; So K; Garnett S; Bannister W; Fabre MA; Dota C; Fielding A
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):775-84. PubMed ID: 27553432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
    Kaufman B; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Steiner M; Loman N; Bowen K; Fielding A; Domchek SM
    J Clin Oncol; 2015 Jan; 33(3):244-50. PubMed ID: 25366685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Olaparib.
    Goulooze SC; Cohen AF; Rissmann R
    Br J Clin Pharmacol; 2016 Jan; 81(1):171-3. PubMed ID: 26344419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
    Moore K; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley W; Mathews C; Liu J; Lowe ES; Bloomfield R; DiSilvestro P
    N Engl J Med; 2018 Dec; 379(26):2495-2505. PubMed ID: 30345884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Olaparib, a new hope for ovarian cancer.
    Samoon Z; Jabbar AA
    Indian J Cancer; 2020; 57(3):346-347. PubMed ID: 32675438
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
    Domchek SM; Aghajanian C; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Loman N; Robertson JD; Mann H; Kaufman B
    Gynecol Oncol; 2016 Feb; 140(2):199-203. PubMed ID: 26723501
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRCA-deficient and triple negative breast cancers: is olaparib effective in both subtypes?
    Sahin I; Ararat E; Altundag K
    J BUON; 2011; 16(1):184-5. PubMed ID: 21674877
    [No Abstract]   [Full Text] [Related]  

  • 34. Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.
    Shimo T; Kurebayashi J; Kanomata N; Yamashita T; Kozuka Y; Moriya T; Sonoo H
    Breast Cancer; 2014 Jan; 21(1):75-85. PubMed ID: 22454224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An olaparib window-of-opportunity trial in patients with early-stage endometrial carcinoma: POLEN study.
    Romero I; Rubio MJ; Medina M; Matias-Guiu X; Santacana M; Schoenenberger JA; Guerra EM; Cortés A; Minig L; Coronado P; Cueva JF; Gómez L; Malfettone A; Sampayo M; Llombart-Cussac A; Poveda A
    Gynecol Oncol; 2020 Dec; 159(3):721-731. PubMed ID: 32988624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maintenance olaparib in advanced ovarian cancer.
    Burki TK
    Lancet Oncol; 2018 Dec; 19(12):e671. PubMed ID: 30509885
    [No Abstract]   [Full Text] [Related]  

  • 37. Stratifying prostate patients for olaparib.
    Cancer Discov; 2015 Jun; 5(6):568-9. PubMed ID: 25904654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein.
    Ghiringhelli F; Richard C; Chevrier S; Végran F; Boidot R
    World J Gastroenterol; 2016 Dec; 22(48):10680-10686. PubMed ID: 28082821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Olaparib Targets Some Advanced Prostate Cancers.
    Cancer Discov; 2016 Jan; 6(1):OF1. PubMed ID: 26658963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Olaparib Keeps Hereditary Breast Tumors in Check.
    Cancer Discov; 2017 Aug; 7(8):OF10. PubMed ID: 28583909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.